title: The effect of interleukin 1 alpha on survival in a murine model of burn wound sepsis.
abstract: We examined the effects of human recombinant interleukin 1 alpha (IL-1 alpha) in a murine model of burn wound sepsis. The BDF1 male mice received a 15% burn injury, followed by burn wound inoculation with Pseudomonas aeruginosa. Improvement in survival was noted in the mice that received a single injection of 100 or 1000 ng of IL-1 alpha in comparison with the control animals (IL-1 alpha, 100 ng vs control, 60% vs 13%; IL-1 alpha, 1000 ng vs control, 40% vs 0%). The animals that received 1 ng twice daily for 7 days had improved survival in comparison with the controls (IL-1 alpha vs control, 70.8% vs 20.8%). The animals that received a single injection of 1000 ng after a bacterial challenge with 10(4) P aeruginosa of IL-1 alpha had fewer positive blood cultures at 48 hours compared with the controls (57% vs 89%). In addition, the animals that received 100 ng of IL-1 alpha had significantly increased absolute neutrophil counts at 6, 24, and 48 hours after thermal injury and bacterial challenge with 10(3) colony-forming units of P aeruginosa. The use of cytokines to modulate the host response to injury or infection may lead to additional strategies to improve the outcome following burn injury.
authors.affiliation: Department of Surgery, University of Vermont College of Medicine, Burlington 05405.
authors.forename: G M
authors.initials: GM
authors.lastname: Silver
authors.forename: R L
authors.initials: RL
authors.lastname: Gamelli
authors.forename: M
authors.initials: M
authors.lastname: O'Reilly
authors.forename: J C
authors.initials: JC
authors.lastname: Hebert
mesh_terms: D000818:Animals; D002056:Burns / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007375:Interleukin-1 / Q000008:administration & dosage / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D051379:Mice; D011552:Pseudomonas Infections / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D011994:Recombinant Proteins / Q000627:therapeutic use; D016019:Survival Analysis; D014946:Wound Infection / Q000097:blood / Q000188:drug therapy* / Q000401:mortality
chemical_list: D007375:Interleukin-1; D011994:Recombinant Proteins